866-997-4948(US-Canada Toll Free)

Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 177 Pages

Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cytomegalovirus (HHV-5) Infections Pipeline Review, H2 2016, provides an overview of the Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline landscape.

Cytomegalovirus (CMV) is a contagious infection of the caused by the member of the herpes virus family. CMV is spread through saliva or urine. Symptoms include fever, pneumonia, weight loss, hearing, neurological and developmental problems. The predisposing factors are exposure direct contact with infected surface or organism, weakened immune system and congenital factors. It may be diagnosed by blood or urine tests. The condition may be controlled by the use of medication such as anti-viral and may be prevented by lifestyle modification.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cytomegalovirus (HHV-5) Infections Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Cytomegalovirus (HHV-5) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cytomegalovirus (HHV-5) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 7, 7, 2, 17, 6 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 4, 7, 5 and 4 molecules, respectively.Cytomegalovirus (HHV-5) Infections.

Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Cytomegalovirus (HHV-5) Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Cytomegalovirus (HHV-5) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cytomegalovirus (HHV-5) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cytomegalovirus (HHV-5) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cytomegalovirus (HHV-5) Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cytomegalovirus (HHV-5) Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Cytomegalovirus (HHV-5) Infections Overview 9
Therapeutics Development 10
Pipeline Products for Cytomegalovirus (HHV-5) Infections - Overview 10
Pipeline Products for Cytomegalovirus (HHV-5) Infections - Comparative Analysis 11
Cytomegalovirus (HHV-5) Infections - Therapeutics under Development by Companies 12
Cytomegalovirus (HHV-5) Infections - Therapeutics under Investigation by Universities/Institutes 14
Cytomegalovirus (HHV-5) Infections - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Cytomegalovirus (HHV-5) Infections - Products under Development by Companies 20
Cytomegalovirus (HHV-5) Infections - Products under Investigation by Universities/Institutes 23
Cytomegalovirus (HHV-5) Infections - Companies Involved in Therapeutics Development 25
Adicet Bio, Inc. 25
AIMM Therapeutics BV 26
Astellas Pharma Inc 27
Atara Biotherapeutics Inc 28
AvidBiotics Corp 29
Biotest AG 30
Chimerix Inc 31
China Biologic Products Inc 32
CyTuVax BV 33
Fate Therapeutics Inc 34
GlaxoSmithKline Plc 35
Hookipa Biotech AG 36
Kadmon Corp LLC 37
Laboratoires Thea SA 38
Merck & Co Inc 39
Microbiotix Inc 40
Mymetics Corp 41
Novartis AG 42
Pfizer Inc 43
Phoenix Biotechnology Inc 44
Savoy Pharmaceuticals, Inc. 45
Sigma-Tau SpA 46
Themis Bioscience GmbH 47
Trellis Bioscience Inc 48
Vakzine Projekt Management GmbH 49
VBI Vaccines Inc 50
Vical Inc 51
Cytomegalovirus (HHV-5) Infections - Therapeutics Assessment 52
Assessment by Monotherapy Products 52
Assessment by Combination Products 53
Assessment by Target 54
Assessment by Mechanism of Action 56
Assessment by Route of Administration 58
Assessment by Molecule Type 60
Drug Profiles 62
AIC-387 - Drug Profile 62
AIC-476 - Drug Profile 63
AIC-813 - Drug Profile 64
AL-18 - Drug Profile 65
Antibody for Human Cytomegalovirus Infection - Drug Profile 66
ASP-0113 - Drug Profile 67
brincidofovir - Drug Profile 70
BT-084 - Drug Profile 84
Cellular Immunotherapy for Cytomegalovirus and Adenovirus Infections - Drug Profile 85
Cellular Immunotherapy for Cytomegalovirus Infections - Drug Profile 86
Cellular Immunotherapy for Cytomegalovirus Infections - Drug Profile 87
Cellular Immunotherapy for Cytomegalovirus Infections - Drug Profile 88
Cellular Immunotherapy for Cytomegalovirus Infections - Drug Profile 89
Cellular Immunotherapy for Cytomegalovirus Infections and GBM - Drug Profile 90
Cellular Immunotherapy for Infectious Disease - Drug Profile 91
Cellular Immunotherapy for Infectious Diseases - Drug Profile 92
Cellular Immunotherapy for Viral Infections - Drug Profile 93
Cellular Immunotherapy for Viral Infections Post-HSCT - Drug Profile 94
Cellular Immunotherapy to Target CMV Antigen for Cytomegalovirus Infections - Drug Profile 95
Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections - Drug Profile 96
Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections - Drug Profile 98
Cellullar Immunotherapy for Viral Infections and Fungal Infections - Drug Profile 99
CMX-669 - Drug Profile 100
CSJ-148 - Drug Profile 101
CyMVectin - Drug Profile 102
cytomegalovirus (virus like particle) vaccine - Drug Profile 104
Cytomegalovirus (virus like particle) vaccine - Drug Profile 105
Cytomegalovirus vaccine - Drug Profile 106
Cytomegalovirus vaccine - Drug Profile 107
Cytomegalovirus vaccine - Drug Profile 108
filociclovir - Drug Profile 109
ganciclovir - Drug Profile 111
Gene Therapy for Cytomegalovirus Infections - Drug Profile 112
HB-101 - Drug Profile 113
letermovir - Drug Profile 114
maribavir - Drug Profile 117
MBX-2168 - Drug Profile 120
Monoclonal Antibodies to Inhibit HLA-A2 for Cytomegalovirus Infections - Drug Profile 121
Monoclonal Antibody for Cytomegalovirus Infections - Drug Profile 122
Monoclonal Antibody to Agonize LTbR for CMV Infection - Drug Profile 123
Pentamer - Drug Profile 124
Peptides to Inhibit Heparan Sulfate for HHV-5 Infections - Drug Profile 125
PepVax - Drug Profile 126
ProTmune - Drug Profile 128
PTX-3 - Drug Profile 130
RBT-301 - Drug Profile 131
Recombinant Peptide for Infectious Diseases - Drug Profile 132
Recombinant Protein for CMV - Drug Profile 133
RKP-00156 - Drug Profile 134
Small Molecule for Cytomegalovirus - Drug Profile 135
Small Molecules for CMV Infections - Drug Profile 136
Small Molecules for CMV infections and Cancer - Drug Profile 137
Small Molecules to Activate Sirtuin for Viral Infections - Drug Profile 138
Small Molecules to Inhibit Acetyl-CoA Carboxylase for CMV Infections - Drug Profile 139
Small Molecules to Inhibit Cyclin-Dependent Kinase 7 for Oncology, Inflammation and Infectious Diseases - Drug Profile 140
Small Molecules to Inhibit Na+/K+ ATPase for Human Cytomegalovirus Infections - Drug Profile 141
Synthetic Peptide to Antagonize VIPR for Cytomegalovirus Infection and Graft Versus Host Disease - Drug Profile 142
Triplex - Drug Profile 143
TRL-345 - Drug Profile 145
V-160 - Drug Profile 146
VBI-1501A - Drug Profile 147
Viralym-C - Drug Profile 149
Viroprev - Drug Profile 150
VPM-2001 - Drug Profile 151
Cytomegalovirus (HHV-5) Infections - Dormant Projects 152
Cytomegalovirus (HHV-5) Infections - Discontinued Products 157
Cytomegalovirus (HHV-5) Infections - Product Development Milestones 158
Featured News & Press Releases 158
Appendix 172
Methodology 172
Coverage 172
Secondary Research 172
Primary Research 172
Expert Panel Validation 172
Contact Us 172
Disclaimer 173

List of Tables
Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H2 2016 14
Number of Products under Development for Cytomegalovirus (HHV-5) Infections - Comparative Analysis, H2 2016 15
Number of Products under Development by Companies, H2 2016 16
Number of Products under Development by Companies, H2 2016 (Contd..1) 17
Number of Products under Investigation by Universities/Institutes, H2 2016 19
Comparative Analysis by Late Stage Development, H2 2016 20
Comparative Analysis by Clinical Stage Development, H2 2016 21
Comparative Analysis by Early Stage Development, H2 2016 22
Comparative Analysis by Unknown Stage Development, H2 2016 23
Products under Development by Companies, H2 2016 24
Products under Development by Companies, H2 2016 (Contd..1) 25
Products under Development by Companies, H2 2016 (Contd..2) 26
Products under Investigation by Universities/Institutes, H2 2016 27
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 28
Cytomegalovirus (HHV-5) Infections - Pipeline by Adicet Bio, Inc., H2 2016 29
Cytomegalovirus (HHV-5) Infections - Pipeline by AIMM Therapeutics BV, H2 2016 30
Cytomegalovirus (HHV-5) Infections - Pipeline by Astellas Pharma Inc, H2 2016 31
Cytomegalovirus (HHV-5) Infections - Pipeline by Atara Biotherapeutics Inc, H2 2016 32
Cytomegalovirus (HHV-5) Infections - Pipeline by AvidBiotics Corp, H2 2016 33
Cytomegalovirus (HHV-5) Infections - Pipeline by Biotest AG, H2 2016 34
Cytomegalovirus (HHV-5) Infections - Pipeline by Chimerix Inc, H2 2016 35
Cytomegalovirus (HHV-5) Infections - Pipeline by China Biologic Products Inc, H2 2016 36
Cytomegalovirus (HHV-5) Infections - Pipeline by CyTuVax BV, H2 2016 37
Cytomegalovirus (HHV-5) Infections - Pipeline by Fate Therapeutics Inc, H2 2016 38
Cytomegalovirus (HHV-5) Infections - Pipeline by GlaxoSmithKline Plc, H2 2016 39
Cytomegalovirus (HHV-5) Infections - Pipeline by Hookipa Biotech AG, H2 2016 40
Cytomegalovirus (HHV-5) Infections - Pipeline by Kadmon Corp LLC, H2 2016 41
Cytomegalovirus (HHV-5) Infections - Pipeline by Laboratoires Thea SA, H2 2016 42
Cytomegalovirus (HHV-5) Infections - Pipeline by Merck & Co Inc, H2 2016 43
Cytomegalovirus (HHV-5) Infections - Pipeline by Microbiotix Inc, H2 2016 44
Cytomegalovirus (HHV-5) Infections - Pipeline by Mymetics Corp, H2 2016 45
Cytomegalovirus (HHV-5) Infections - Pipeline by Novartis AG, H2 2016 46
Cytomegalovirus (HHV-5) Infections - Pipeline by Pfizer Inc, H2 2016 47
Cytomegalovirus (HHV-5) Infections - Pipeline by Phoenix Biotechnology Inc, H2 2016 48
Cytomegalovirus (HHV-5) Infections - Pipeline by Savoy Pharmaceuticals, Inc., H2 2016 49
Cytomegalovirus (HHV-5) Infections - Pipeline by Sigma-Tau SpA, H2 2016 50
Cytomegalovirus (HHV-5) Infections - Pipeline by Themis Bioscience GmbH, H2 2016 51
Cytomegalovirus (HHV-5) Infections - Pipeline by Trellis Bioscience Inc, H2 2016 52
Cytomegalovirus (HHV-5) Infections - Pipeline by Vakzine Projekt Management GmbH, H2 2016 53
Cytomegalovirus (HHV-5) Infections - Pipeline by VBI Vaccines Inc, H2 2016 54
Cytomegalovirus (HHV-5) Infections - Pipeline by Vical Inc, H2 2016 55
Assessment by Monotherapy Products, H2 2016 56
Assessment by Combination Products, H2 2016 57
Number of Products by Stage and Target, H2 2016 59
Number of Products by Stage and Mechanism of Action, H2 2016 61
Number of Products by Stage and Route of Administration, H2 2016 63
Number of Products by Stage and Molecule Type, H2 2016 65
Cytomegalovirus (HHV-5) Infections - Dormant Projects, H2 2016 156
Cytomegalovirus (HHV-5) Infections - Dormant Projects (Contd..1), H2 2016 157
Cytomegalovirus (HHV-5) Infections - Dormant Projects (Contd..2), H2 2016 158
Cytomegalovirus (HHV-5) Infections - Dormant Projects (Contd..3), H2 2016 159
Cytomegalovirus (HHV-5) Infections - Dormant Projects (Contd..4), H2 2016 160
Cytomegalovirus (HHV-5) Infections - Discontinued Products, H2 2016 161

List of Figures
Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H2 2016 14
Number of Products under Development for Cytomegalovirus (HHV-5) Infections - Comparative Analysis, H2 2016 15
Number of Products under Development by Companies, H2 2016 16
Number of Products under Investigation by Universities/Institutes, H2 2016 18
Comparative Analysis by Late Stage Development, H2 2016 20
Comparative Analysis by Clinical Stage Development, H2 2016 21
Comparative Analysis by Early Stage Products, H2 2016 22
Assessment by Monotherapy Products, H2 2016 56
Number of Products by Top 10 Targets, H2 2016 58
Number of Products by Stage and Top 10 Targets, H2 2016 58
Number of Products by Top 10 Mechanism of Actions, H2 2016 60
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 60
Number of Products by Routes of Administration, H2 2016 62
Number of Products by Stage and Routes of Administration, H2 2016 62
Number of Products by Top 10 Molecule Types, H2 2016 64
Number of Products by Stage and Top 10 Molecule Types, H2 2016 64

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *